Algenscribe develops genome editing tools for gene therapy and bioproduction.
AlgenScribe has raised $541K in total funding. The most recent round was Seed. The last funding was announced in November 2025.
AlgenScribe's investors include YES invest.
AlgenScribe is headquartered in Nice, France.
Algenscribe develops genome editing tools for gene therapy and bioproduction.
AlgenScribe is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AlgenScribe — Funding & Investors." VCBacked, November 21, 2025, https://www.vcbacked.co/company/algenscribe. Accessed August 1, 2026.
VCBacked. (2025). AlgenScribe — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/algenscribe
{{cite web |title=AlgenScribe — Funding & Investors |url=https://www.vcbacked.co/company/algenscribe |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated